studies

non squamous - mNSCLC - L1 - Wild Type (WT), immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-130 (WT), 2019 0.79 [0.64; 0.98] IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96] KEYNOTE-021, 2016 0.90 [0.42; 1.92] KEYNOTE-189, 2018 0.49 [0.38; 0.64] 0.70[0.54; 0.90]IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC WT), 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018470%2,114moderatenot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-021, 2016 0.71 [0.45; 1.12] KEYNOTE-189, 2018 0.56 [0.45; 0.70] 0.59[0.48; 0.71]KEYNOTE-021, 2016, KEYNOTE-189, 201820%739lownot evaluable PFS (extension)detailed resultsKEYNOTE-021, 2016 0.54 [0.35; 0.83] KEYNOTE-189, 2018 0.48 [0.40; 0.58] 0.49[0.41; 0.58]KEYNOTE-021, 2016, KEYNOTE-189, 201820%739lownot evaluable progression or deaths (PFS)detailed resultsIMpower-130 (WT), 2019 0.64 [0.54; 0.76] IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68] IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74] KEYNOTE-021, 2016 0.53 [0.31; 0.91] KEYNOTE-189, 2018 0.52 [0.43; 0.63] 0.58[0.53; 0.64]IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, KEYNOTE-021, 2016, KEYNOTE-189, 201850%2,394moderatenot evaluable DORdetailed resultsIMpower-130 (WT), 2019 2.41 [1.27; 4.60] 2.41[1.27; 4.60]IMpower-130 (WT), 201910%292NAnot evaluable objective responses (ORR)detailed resultsIMpower-130 (WT), 2019 2.07 [1.48; 2.89] IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19] IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55] KEYNOTE-021, 2016 3.06 [1.45; 6.45] KEYNOTE-189, 2018 3.88 [2.61; 5.79] 2.38[1.78; 3.19]IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018559%2,376moderatenot evaluable objective responses (ORR) (extension)detailed resultsKEYNOTE-021, 2016 2.80 [1.34; 5.83] KEYNOTE-189, 2018 3.84 [2.58; 5.70] 3.57[2.52; 5.06]KEYNOTE-021, 2016, KEYNOTE-189, 201820%739lownot evaluable AE (any grade)detailed resultsKEYNOTE-189, 2018 4.04 [0.36; 44.82] 4.04[0.36; 44.82]KEYNOTE-189, 201810%607NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.03 [0.73; 1.45] 1.03[0.73; 1.45]KEYNOTE-189, 201810%607NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-189, 2018 1.13 [0.56; 2.28] 1.13[0.56; 2.28]KEYNOTE-189, 201810%607NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-189, 2018 2.19 [1.31; 3.65] 2.19[1.31; 3.65]KEYNOTE-189, 201810%607NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.04 [1.16; 3.59] 2.04[1.16; 3.59]KEYNOTE-189, 201810%607NAnot evaluable STRAE (any grade)detailed resultsKEYNOTE-021, 2016 3.47 [1.25; 9.62] 3.47[1.25; 9.62]KEYNOTE-021, 201610%121NAnot evaluable STRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 5.56 [1.49; 20.67] 5.56[1.49; 20.67]KEYNOTE-021, 201610%121NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-021, 2016 0.95 [0.29; 3.12] 0.95[0.29; 3.12]KEYNOTE-021, 201610%121NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.04 [0.92; 4.52] 2.04[0.92; 4.52]KEYNOTE-021, 201610%121NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-021, 2016 0.52 [0.05; 5.86] 0.52[0.05; 5.86]KEYNOTE-021, 201610%121NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-021, 2016 0.76 [0.25; 2.35] 0.76[0.25; 2.35]KEYNOTE-021, 201610%121NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.44 [0.48; 40.91] 4.44[0.48; 40.91]KEYNOTE-021, 201610%121NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.32 [0.19; 97.73] 4.32[0.19; 97.73]KEYNOTE-021, 201610%121NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.03; 8.00] 0.50[0.03; 8.00]KEYNOTE-189, 201810%607NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.79 [0.27; 2.29] 0.79[0.27; 2.29]KEYNOTE-021, 201610%121NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 3.01 [0.15; 60.33] 3.01[0.15; 60.33]KEYNOTE-189, 201810%607NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] 0.52[0.02; 15.84]KEYNOTE-021, 201610%121NAnot evaluable Dizziness TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.32 [0.19; 97.73] 4.32[0.19; 97.73]KEYNOTE-021, 201610%121NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 4.02 [0.21; 76.41] 4.02[0.21; 76.41]KEYNOTE-189, 201810%607NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.72[0.04; 11.64]KEYNOTE-021, 2016, KEYNOTE-189, 201820%728lownot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-189, 2018 2.00 [0.09; 44.56] 1.56[0.14; 17.88]KEYNOTE-021, 2016, KEYNOTE-189, 201820%728lownot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] 1.05[0.06; 17.21]KEYNOTE-021, 201610%121NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] 1.05[0.06; 17.21]KEYNOTE-021, 201610%121NAnot evaluable Increased lacrimation (TRAE grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.45[0.13; 16.15]KEYNOTE-021, 2016, KEYNOTE-189, 201820%728lownot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 6.06 [0.34; 109.04] 6.06[0.34; 109.04]KEYNOTE-189, 201810%607NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.14 [0.19; 24.25] 2.14[0.19; 24.25]KEYNOTE-021, 201610%121NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.00 [0.09; 44.56] 2.00[0.09; 44.56]KEYNOTE-189, 201810%607NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] 0.52[0.02; 15.84]KEYNOTE-021, 201610%121NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-189, 2018 1.00 [0.30; 3.35] 1.09[0.35; 3.40]KEYNOTE-021, 2016, KEYNOTE-189, 201820%728lownot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] KEYNOTE-189, 2018 1.00 [0.30; 3.35] 1.01[0.33; 3.06]KEYNOTE-021, 2016, KEYNOTE-189, 201820%728lownot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] 0.52[0.02; 15.84]KEYNOTE-021, 201610%121NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.14; 7.73] 1.05[0.14; 7.73]KEYNOTE-021, 201610%121NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.07 [0.67; 1.71] 1.07[0.67; 1.71]KEYNOTE-189, 201810%607NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.83 [0.78; 4.31] 1.83[0.78; 4.31]KEYNOTE-189, 201810%607NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.00 [0.22; 18.06] 2.00[0.22; 18.06]KEYNOTE-189, 201810%607NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 3.02 [0.36; 25.28] 3.02[0.36; 25.28]KEYNOTE-189, 201810%607NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.79 [0.71; 4.50] 1.79[0.71; 4.50]KEYNOTE-189, 201810%607NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.67 [0.30; 1.48] 0.67[0.30; 1.48]KEYNOTE-189, 201810%607NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.37 [0.89; 6.34] 2.37[0.89; 6.34]KEYNOTE-189, 201810%607NAnot evaluable Lacrimation increased AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.40; 2.51] 1.00[0.40; 2.51]KEYNOTE-189, 201810%607NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.39 [0.84; 2.30] 1.39[0.84; 2.30]KEYNOTE-189, 201810%607NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.17 [0.30; 4.56] 1.17[0.30; 4.56]KEYNOTE-189, 201810%607NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.15 [0.60; 2.21] 1.15[0.60; 2.21]KEYNOTE-189, 201810%607NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.26 [0.48; 3.29] 1.26[0.48; 3.29]KEYNOTE-189, 201810%607NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:36 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 176 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743